AMENDMENTS

Please amend the claims as follows:

Please cancel claims 3, 30-32, 36-43, 45, 55, 56, 65 and 74-83.

1. (Currently amended) A method of classifying a population by drug responsiveness, comprising:

(a) creating a multidimensional space of n dimensions, wherein n represents the number of different molecules being analyzed in a specimen from each individual in a population of individuals administered a drug and wherein said multidimensional space contains n axes, each of said axes relating to the expression level of a molecule of said n molecules, wherein n is 3 or more molecules;

(b) determining a multidimensional coordinate point for each individual, wherein said multidimensional coordinate point is representative of the expression levels of said n molecules; and

(c) determining a drug response-associated reference expression region of a group of individuals in said population using said multidimensional coordinate points, thereby classifying said group of individuals into a drug response reference population.

2. (Original) The method of claim 1, further comprising the step of correlating said group of individuals with a response to said drug.

Claim 3 (Canceled).

4. (Original) The method of claim 2, wherein said response is alleviation of a sign or symptom associated with a condition of an individual administered said drug.

Claims 5-7. (Canceled)

8. (Previously presented) The method of claim 1, wherein the expression levels of said molecules are determined by contacting said specimen with a target.

9. (Original) The method of claim 1, wherein said specimen is selected from the group consisting of leukocytes, blood, and serum.

10. (Original) The method of claim 8, wherein said target is an array.

11. (Original) The method of claim 1, wherein said molecules in said specimen comprise nucleic acids.

12. (Original) The method of claim 8, wherein said target comprises nucleic acid ligands.

13. (Original) The method of claim 1, wherein said molecules in said specimen comprise polypeptides.

14. (Original) The method of claim 8, wherein said target comprises antibody ligands.

15. (Original) The method of claim 1, wherein said molecules in said specimen comprise small molecules.

16. (Currently amended) A method of classifying a population by drug responsiveness, comprising:

(a) creating a multidimensional space of n dimensions, wherein n represents the number of different molecules being analyzed in a specimen comprising leukocytes from each individual in a population of individuals administered a drug and wherein said multidimensional space contains n axes, each of said axes relating to the expression level of a molecule of said n molecules, wherein n is 3 or more molecules;

(b) determining a multidimensional coordinate point for each individual, wherein said multidimensional coordinate point is representative of the expression levels of said n molecules; and

(c) determining a drug response-associated reference expression region of a group of individuals in said population using said multidimensional coordinate points, thereby classifying said group of individuals into a drug response reference population.

Claims 17 – 43 (Canceled).

44. (Previously presented) The method of claim 16, further comprising the step of correlating said group of individuals with a response to said drug.

Claim 45 (Canceled).

46. (Previously presented) The method of claim 44, wherein said response is alleviation of a sign or symptom associated with a condition of an individual administered said drug.

Claim 47 (Canceled).

48. (Previously presented) The method of claim 16, wherein the expression levels of said molecules are determined by contacting said specimen with a target.

49. (Previously presented) The method of claim 48, wherein said target is an array.

50. (Previously presented) The method of claim 16, wherein said molecules in said specimen comprise nucleic acids.

51. (Previously presented) The method of claim 48, wherein said target comprises nucleic acid ligands.

52. (Previously presented) The method of claim 16, wherein said molecules in said specimen comprise polypeptides.

53. (Previously presented) The method of claim 48, wherein said target comprises antibody ligands.

54. (Previously presented) The method of claim 16, wherein said molecules in said specimen comprise small molecules.

Claims 55 and 56 (Canceled).

57. (Previously presented) The method of claim 1, wherein n is 5 or more molecules.

58. (Previously presented) The method of claim 1, wherein n is 10 or more molecules.

59. (Previously presented) The method of claim 1, wherein n is 20 or more molecules.

60. (Previously presented) The method of claim 1, wherein n is 50 or more molecules.

61. (Previously presented) The method of claim 1, wherein n is 100 or more molecules.

62. (Previously presented) The method of claim 1, wherein n is 200 or more molecules.

63. (Previously presented) The method of claim 1, wherein n is 500 or more molecules.

64. (Previously presented) The method of claim 1, wherein n is 1000 or more molecules.

Claim 65 (Canceled).

66. (Previously presented) The method of claim 16, wherein n is 5 or more molecules.

67. (Previously presented) The method of claim 16, wherein n is 10 or more molecules.

68. (Previously presented) The method of claim 16, wherein n is 20 or more molecules.

69. (Previously presented) The method of claim 16, wherein n is 50 or more molecules.

70. (Previously presented) The method of claim 16, wherein n is 100 or more molecules.

71. (Previously presented) The method of claim 16, wherein n is 200 or more molecules.

72. (Previously presented) The method of claim 16, wherein n is 500 or more molecules.

73. (Previously presented) The method of claim 16, wherein n is 1000 or more molecules.

Claims 74-83 (Canceled).